Fludarabine with cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukemia (CLL):: Final results of a phase II study.

被引：0
|
作者：
Bosch, F
Ferrer, A
López-Guillermo, A
Giné, E
Cobo, F
Perales, M
Esteve, J
Villamor, N
Colomer, D
Bellosillo, B
Ribera, JM
Altes, A
Besalduch, J
Montserrat, E
机构：
[1] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
[2] Hosp Sarit Pau, Dept Hematol, Barcelona, Spain
[3] Hosp Germans Trias & Pujol, Dept Hematol, Badalona, Spain
[4] Hosp Son Dureta, Dept Hematol, Palma de Mallorca, Spain
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2655
引用
收藏
页码：634A / 634A
页数：1
相关论文
共 50 条
  • [1] Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL).
    Bosch, F
    Perales, M
    Cobo, F
    Esteve, J
    Rafel, M
    LopezGuillermo, A
    Ribera, JM
    Campo, E
    Montserrat, E
    BLOOD, 1997, 90 (10) : 2360 - 2360
  • [2] Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
    Bosch, F
    Ferrer, A
    López-Guillermo, A
    Giné, E
    Bellosillo, B
    Villamor, N
    Colomer, D
    Cobo, F
    Perales, M
    Esteve, J
    Altés, A
    Besalduch, J
    Ribera, JM
    Montserrat, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (04) : 976 - 984
  • [3] Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) as frontline therapy for CLL: Results of a phase 2 study.
    Faderl, Stefan
    Wierda, William G.
    O'Brien, Susan
    Ferrajoli, Alessandra
    Ravandi-Kashani, Farhad
    Detry, Michelle
    Kantarjian, Hagop M.
    O'Neal, Brandi
    Keating, Michael J.
    BLOOD, 2006, 108 (11) : 803A - 803A
  • [4] Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)
    Bosch, Francesc
    Abrisqueta, Pau
    Villamor, Neus
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Gonzalez, Marcos
    Ferra, Christelle
    Abella, Eugenia
    Delgado, Julio
    Garcia-Marco, Jose A.
    Gonzalez, Yolanda
    Carbonell, Felix
    Ferrer, Secundino
    Monzo, Encarna
    Jarque, Isidro
    Muntanola, Ana
    Constants, Mireia
    Escoda, Lourdes
    Montserrat, Emili
    BLOOD, 2011, 118 (21) : 136 - 137
  • [5] Update of experience with fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline therapy for chronic lymphocytic leukemia (CLL)
    Faderl, Stefan
    Wierda, William
    Ferrajoli, Alessandra
    O'Brien, Susan
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Showalter, Brandi L.
    Lerner, Susan
    Keating, Michael J.
    BLOOD, 2007, 110 (11) : 193A - 194A
  • [6] Interim results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in previously untreated chronic lymphocytic leukemia (CLL)
    Bosch, F.
    Muntanola, A.
    Villamor, N.
    Terol, M.
    Gonzalez-Barca, E.
    Ribera, J.
    Gonzalez, M.
    Abella, E.
    Delgado, J.
    Carbonell, F.
    Marco, J. Garcia
    Escoda, L.
    Ferrer, S.
    Monzo, E.
    Gonzalez, Y.
    de la Serna, J.
    Abrisqueta, P.
    Gine, E.
    Salamero, O.
    Montserrat, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
  • [7] Phase II study of fludarabine and mitoxantrone in patients with chronic lymphocytic leukemia.
    Tsimberidou, AM
    Keating, MJ
    Giles, F
    Lerner, S
    Kantarjian, HM
    O'Brien, S
    BLOOD, 2003, 102 (11) : 358B - 358B
  • [8] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
    O'Brien, S.
    Byrd, J. C.
    Kipps, T. J.
    Forero-Torres, A.
    Flinn, I. W.
    Wynne, D. I.
    Molina, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [9] Fludarabine, mitoxantrone and cyclophosphamide combination therapy in relapsed chronic lymphocytic leukemia (CLL) with or without G-CSF: Results of the first interim ananlysis of a phase III study of the German CLL study group (GCLLSG).
    Schmitt, BF
    Franke, A
    Burkhard, O
    Schlag, R
    Hopfinger, G
    Stauch, M
    Bergmann, M
    Wendtner, CM
    Busch, R
    Emmerich, B
    Hallek, N
    BLOOD, 2002, 100 (11) : 364B - 364B
  • [10] Fludarabine (FAMP) and mitoxantrone therapy in chronic lymphocytic leukemia (CLL).
    OBrien, S
    Kantarjian, H
    Beran, M
    Robertson, IE
    Freireich, E
    Kornblau, S
    Koller, C
    Estey, E
    Lerner, S
    Keating, M
    BLOOD, 1996, 88 (10) : 2341 - 2341
12345